Article PDF
Avoid common mistakes on your manuscript.
References
Yamamoto T, Ikawa S, Akaiyama T et al (1986) Similarity of protein encoded by the human cerb- B-2 gene to epidermal growth factor receptor. Nature 319:230–234
Cortes-Funes H, Rivera F, Ales I et al (2007) Phase II trial of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with Her2/neu overexpression/amplification. J Clin Oncol 2007 (ASCO Annual Meeting Proceedings) Part I. 26[18S, June 20 Suppl]:abstract 4613
Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687–697
Gomez-Martin C, Concha A, Corominas JM et al (2011) Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol 13:636–651
Ruschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cance: guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307
National Health Service (2010) NICE technology appraisal guidance 208: trastuzumab for the treatment of HER2-positive metastatic gastric cancer. November
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lordick, F. HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin Transl Oncol 13, 597–598 (2011). https://doi.org/10.1007/s12094-011-0704-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0704-z